Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Outsourcing-Pharma

16:33 EDT 20th August 2018 | BioPortfolio

Here are the most relevant search results for "Outsourcing-Pharma" found in our extensive news archives from over 250 global news sources.

More Information about Outsourcing-Pharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Outsourcing-Pharma for you to read. Along with our medical data and news we also list Outsourcing-Pharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Outsourcing-Pharma Companies for you to search.

Showing News Articles 1–25 of 440 from Outsourcing-Pharma

Monday 20th August 2018

US FDA warns CRO against storing specimens in tissue and supply closet

The US FDA has issued a warning letter to North American Science Associates, following an inspection of the CROâs Brooklyn Park facility in Minnesota.

Sygnature Discovery doubling DMPK department, recruitment program ongoing

Sygnature Discovery is adding a new facility at Alderley Park in Cheshire, UK in response to an increasing demand for outsourced preclinical research services.

CROs respond: FDA guidance on expansion cohort use in FIH trials a ‘welcome step’

Industry executives are welcoming the FDAâs draft guidance on expansion cohort use in first-in-human clinical trials â the increasing use of which is evidence of a changing drug development paradigm, says CRO.

Syneos acquires consulting firm to boost regulatory, safety, pharmacovigilance capabilities

Syneos Health has acquired the UK-based advisory firm Kinapse in a deal that will double its consulting footprint in Europe and further strengthen its commercial offerings â one company's fastest-growing lines of business, says CEO.

Thursday 16th August 2018

VIARES granted IAOCR 5-Star accreditation for its CRA training program

VIARESâ training program was developed to train entry-level CRAs â a vital role in the clinical research industry for which there has been a significant shortage.

Charles River eyes global M&A opportunities, expects to double size in 5 years

Fueled by increasing investments from biotech, Charles River expects to double the size of its business over the next five years â organically and through M&A â to become a âmore responsive partner,â says CEO.

Evotec tapped for preclinical studies of BioTherapeutics’ lead pipeline candidate

Evotec is conducting preclinical and toxicology/safety studies for Stealth BioTherapeuticsâ lead candidate, ahead of clinical trials slated to begin in 2019.

Evotec tapped for preclinical studies of BioTherapeutics’ lead candidate

Evotec is conducting preclinical and toxicology/safety studies for BioTherapeuticsâ lead candidate, ahead of clinical trials slated to begin in 2019.

Trans-Hit Bio signs commercial agreement with Arizona hospital

Trans-Hit Bio, a worldwide CRO, has signed a commercial agreement with the biobank of Arizonaâs Maricopa Integrated Health System.

Wednesday 15th August 2018

UK reaffirms commitment to ‘a competitive service for clinical trial assessment’ post Brexit

In an update on the implementation of the new Clinical Trials Regulation, the MHRA expresses increased confidence that the UK will exit the EU with a deal â and reaffirms its commitment to align with parts of the legislation âwithin the UKâs control.â

Albumedix enters evaluation agreement with Novartis

Novartis will use Albumedixâs Veltis drug delivery technology platform to develop several first-in-class therapeutics.

Tuesday 14th August 2018

Fusion Antibodies: FY19 to miss on expectations due to ‘increasing competition’

The UK-based CRO anticipates that its FY19 earnings results will be âsignificantly behind current market expectations,â due to increasing competition and pricing pressures.

Catalent completes Juniper merger to ‘expand and strengthen’ oral dose manufacturing

Juniper Pharmaceuticals will become a wholly owned subsidiary of Catalent Pharma Solutions today, says the CDMO.

Clinical, commercial cross-selling fuels record Q2 at Syneos

Collaboration and cross-selling across Syneos Health's clinical and commercial organizations drove a record quarter marked by new strategic relationships as customers look to increase outsourcing in response to pricing pressures.

Monday 13th August 2018

PRA talks accelerated Symphony integration, staffing on Q2 earnings call

PRA Health Sciencesâ Q2 revenue is up 35%, as the CRO accelerates integration plans with Symphony Health and predicts an increase in staff towards the end of the year.

India poised to become ‘one of the largest clinical trial hubs,’ says CRO

Regulatory changes have brought clinical research in India âback on trackâ â with the market expected to grow at a CAGR of approximately 12%.

Bioanalytics CRO joins Science Exchange marketplace

Antibody Analytics and Science Exchange have announced a collaboration that aims to provide bioanalytical services to the global research community.

Almac and Elasmogen receive £2m grant for oncology research

Almac Discovery is collaborating with Elasmogen to further oncology research after being granted Â2m by Innovate UK.

Thursday 9th August 2018

New Icon collab looks to meet demand for real world evidence

Icon and Practice Fusion have teamed up to meet the expanding demand for real world evidence â and aim to transform the way research is conducted.

Certara outlines the role of quantitative systems pharmacology in FIH trial design, EMA responds

Modeling and simulation can provide âmeaningful predictionâ of a drugâs pharmacodynamic range and maximum dose â the use of which might have prevented the tragic outcome of the BIAL 10-2474 trial in 2016, says Certara VP.

CRISPR research deal will attract new business, says Oxford Genetics

Oxford Genetics has signed a supply and licensing agreement for CRISPR engineered mammalian cell line with an unnamed ecommerce firm.

Medpace surprises with Q2 2018 revenue growth: ‘Things have been running very smoothly’

Revenue growth has taken off, driven by steady start-up on several programs, as the CRO remains focused on its core market of small and midsized biopharma â which makes up the majority of its revenue.

Wednesday 8th August 2018

Robotics, automation to play a ‘fundamental role’ in Icon’s continued success: Q2 earnings call

Robotics and automation will help improve the clunky and expensive clinical trial process, says Icon CEO â as the company continues to evaluate potential opportunities to improve efficiency.

State of the Industry: What readers have to say

Outsourcing-Pharma recently conducted a second âstate of the industryâ survey to gauge views about the current state of the global pharmaceutical outsourcing market and the evolving relationships of those involved.

Applied BioMath supporting Ph I trial of Northern Biologics’ lead antibody therapeutic

Applied BioMath is providing clinical pharmacology and semi-mechanistic PK/PD modeling support for Northern Biologics Phase I clinical trial.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks